http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 08:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+18/26663226.html si-local-file:///var/storage/secattach/20260618/26663226.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+18/26663226.html Thu, 18 Jun 2026 08:16:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+18/26663226.html si-local-file:///var/storage/secattach/20260618/26663226.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+18/26663226.html Thu, 18 Jun 2026 08:16:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+18/26663126.html si-local-file:///var/storage/secattach/20260618/26663126.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+18/26663126.html Thu, 18 Jun 2026 08:01:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+18/26663126.html si-local-file:///var/storage/secattach/20260618/26663126.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+18/26663126.html Thu, 18 Jun 2026 08:01:00 -0400 GRCE O.07433357 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html <p align="center"><em>Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission</em></p> <p align="center"><em>Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences</em></p> <p align="center"><em>Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA</em><br/><em>Resubmission for GTx-104 for the Treatment of Patients with aSAH</em></p> <p align="justify">PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+2026+Fiscal+Year-End+Financial+Results%2C+Provides+Business+Update/26663100.html Thu, 18 Jun 2026 08:00:00 -0400 A.01908724 A.50208593 A.50216777 A.60012014 GRCE O.00303771 O.07433357 O.20988509 O.29757805 O.54516537 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Grace+Therapeutics%2C+Inc.++For%3A+Mar+31/26662843.html si-local-file:///var/storage/secattach/20260618/26662843.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Grace+Therapeutics%2C+Inc.++For%3A+Mar+31/26662843.html Thu, 18 Jun 2026 07:31:00 -0400 GRCE O.07433357